EMA and NICE Appraisal Processes for Cancer Drugs : Current Status and Uncertainties
Citation
Dickson , R , Boland , A , Duarte , R , Kotas , E , Woolacott , N , Hodgson , R , Riemsma , R , Grimm , S , Ramaekers , B , Joore , M , Büyükkaramikli , N , Kaltenthaler , E , Stevenson , M , Pandor , A , Edwards , S , Hoyle , M , Shepherd , J , Armoiry , X & Brazzelli , M 2018 , ' EMA and NICE Appraisal Processes for Cancer Drugs : Current Status and Uncertainties ' , Applied Health Economics and Health Policy , vol. 16 , no. 4 , pp. 429-432 . https://doi.org/10.1007/s40258-018-0393-7
Rights
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.